The ROS1 oncogenic fusion protein can be targeted by the ALK/ROS1/MET TKI crizotinib8,9, which is approved for the treatment of metastatic ROS1-rearranged NSCLC. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.